Lexaria Bioscience Corp Total Liabilities
Lexaria Bioscience Corp total liabilities. Based on the latest financial reports, Lexaria Bioscience Corp (LEXX) has total liabilities worth $437.09K USD as of May 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check LEXX cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Lexaria Bioscience Corp (2005–2025)
Total liabilities of Lexaria Bioscience Corp from 2005 to 2025. This chart illustrates how Lexaria Bioscience Corp's total liabilities have evolved over time, based on quarterly financial data.
Lexaria Bioscience Corp Competitors by Total Liabilities
The table below lists competitors of Lexaria Bioscience Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Costain Group PLC
LSE:COST
|
UK | GBX325.40 Million |
|
ENENSYS Technologies SA
PA:ALNN6
|
France | €13.00 Million |
|
HEBEI YICHEN GRP H YC 05
F:HE2
|
Germany | €1.15 Billion |
|
Miraculum SA
WAR:MIR
|
Poland | zł29.04 Million |
|
E-Pango SA
PA:ALAGO
|
France | €3.04 Million |
|
HEBEI CONSTR.GRP CORP YC1
F:H9D
|
Germany | €42.04 Billion |
|
Theriva Biologics Inc.
NYSE MKT:TOVX
|
USA | $22.85 Million |
|
ENERGY S.P.A.
F:S2I
|
Germany | €21.49 Million |
Liability Composition Analysis (2005–2025)
This chart breaks down Lexaria Bioscience Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Lexaria Bioscience Corp total assets.
Liquidity & Leverage Metrics
Lexaria Bioscience Corp Total Liabilities Ratios Explained
Lexaria Bioscience Corp total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lexaria Bioscience Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lexaria Bioscience Corp (2005–2025)
The table below shows the annual total liabilities of Lexaria Bioscience Corp from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-08-31 | $1.57 Million | +30.08% |
| 2024-08-31 | $1.21 Million | +199.26% |
| 2023-08-31 | $403.91K | +100.51% |
| 2022-08-31 | $201.44K | -0.90% |
| 2021-08-31 | $203.26K | -41.25% |
| 2020-08-31 | $345.98K | +87.52% |
| 2019-08-31 | $184.51K | +322.79% |
| 2018-08-31 | $43.64K | -52.74% |
| 2017-08-31 | $92.35K | -80.72% |
| 2016-08-31 | $478.88K | +768.72% |
| 2015-08-31 | $55.12K | -96.26% |
| 2014-08-31 | $1.47 Million | 0.00% |
| 2013-08-31 | $1.47 Million | +1.14% |
| 2012-08-31 | $1.46 Million | -13.12% |
| 2011-08-31 | $1.68 Million | +13.67% |
| 2010-08-31 | $1.48 Million | +21.68% |
| 2009-08-31 | $1.21 Million | +53.92% |
| 2008-08-31 | $788.18K | +96.56% |
| 2007-08-31 | $400.98K | -80.10% |
| 2006-08-31 | $2.01 Million | +17928.53% |
| 2005-08-31 | $11.18K | -- |
About Lexaria Bioscience Corp
Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall … Read more